Yarrow Bioscience (YARW) Current Assets (2016 - 2026)
Yarrow Bioscience's (YARW) quarterly Current Assets came in at $25.8 million in Q1 2026, down 53.04% YoY from $54.9 million in Q1 2025, and down 14.07% on a QoQ basis from $30.0 million in Q4 2025.
Yarrow Bioscience (YARW) Current Assets (2016 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 11 years of Current Assets data on file, last reported at $25.8 million in Q1 2026.
- Quarterly Current Assets fell 53.04% year-over-year to $25.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.8 million (down 53.04% YoY) and the FY2025 annual result came in at $30.0 million, down 53.43% from the prior year.
- Current Assets retreated to $25.8 million in Q1 2026, from $30.0 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $96.0 million in Q4 2023 to a low of $17.5 million in Q3 2023.
- A 5-year average of $52.0 million and a median of $48.1 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets tumbled 60.24% — and 2024, when it soared 319.94%.
- Tracing YARW's Current Assets over 5 years: stood at $38.3 million in 2022, then surged by 150.72% to $96.0 million in 2023, then slumped by 32.85% to $64.4 million in 2024, then sank by 53.43% to $30.0 million in 2025, then declined by 14.07% to $25.8 million in 2026.
- The last three Current Assets figures came in at $25.8 million (Q1 2026), $30.0 million (Q4 2025), and $44.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | 23.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.53 Mn |
| Mar 31, 2026 | 25.79 Mn |
| Dec 31, 2025 | 30.01 Mn |
| Jun 30, 2025 | 44.34 Mn |
| Mar 31, 2025 | 54.91 Mn |
| Dec 31, 2024 | 64.44 Mn |
| Sep 30, 2024 | 73.54 Mn |
| Jun 30, 2024 | 83.78 Mn |
| Mar 31, 2024 | 90.22 Mn |
| Dec 31, 2023 | 95.96 Mn |
| Sep 30, 2023 | 17.51 Mn |
| Jun 30, 2023 | 22.96 Mn |
| Mar 31, 2023 | 33.02 Mn |
| Dec 31, 2022 | 38.28 Mn |
| Sep 30, 2022 | 44.05 Mn |
| Jun 30, 2022 | 51.92 Mn |
| Mar 31, 2022 | 60.65 Mn |
| Dec 31, 2021 | 63.19 Mn |
| Sep 30, 2021 | 76.13 Mn |
| Jun 30, 2021 | 128.43 Mn |